AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00820651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and lifestyle counseling
Description: Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with \<10% of saturated fatty acids and protein 14%, and exercise)
Study NCT01220895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-specific T-cells, single infusion following single positive CMV PCR result
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Study NCT01220895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CMV-specific T-cells, single infusion following single positive CMV PCR result
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Study NCT06458803 — intervention group
Intervention type: DRUG
Intervention: Eltrombopag
Description: patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.
Study NCT03382795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR
Description: Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
Study NCT03286842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
Study NCT00915681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: 20 mg/kg continuous IV is over 24 hours
Study NCT04318899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy adapted for adolescents (DBT-A)
Description: DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
Study NCT04318899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy - Standard version (DBT)
Description: DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
Study NCT03724864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: delivery of snacks
Description: Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
Study NCT03724864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: delivery of snacks
Description: Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
Study NCT03724864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: delivery of snacks
Description: Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
Study NCT02797808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Impact of sertraline on functional brain connectivity
Study NCT02797808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Healthy control non-intervention
Study NCT03048669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement
Description: A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
Study NCT04089007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOmNI app
Description: In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
Study NCT04089007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
Study NCT04469413 — intervention group
Intervention type: DRUG
Intervention: Paracetamol Infusion
Description: Continuous and Standard Intermittent Boluses Paracetamol Infusion
Study NCT04648384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blend Protein Supplementation
Description: Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
Study NCT04648384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
Study NCT04648384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise
Description: 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
Study NCT04648384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
Study NCT05272800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectroscopy Bioimpedance Analysis
Description: Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
Study NCT05272800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Examination alone
Description: The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
Study NCT00601068 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Group of patients with osteochemonecrosis related to oral bisphosphonate use
Study NCT03659682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide
Description: subcutaneous, 1.0 mg, weekly, 48 months
Study NCT03659682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: subcutaneous, 1.0 mg, weekly, 48 months
Study NCT01072214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: gw786034
Study NCT01072214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04840160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: A tart cherry juice intervention
Study NCT04840160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A tart cherry juice placebo
Study NCT02057315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELS-M11
Description: One dose of 5% ELS-M11 over 3 bilateral applications.
Study NCT02057315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ELS-M11
Description: One dose of 5% ELS-M11 over 3 bilateral applications.
Study NCT02057315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose of matching placebo over 3 bilateral applications.
Study NCT02057315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of matching placebo over 3 bilateral applications.
Study NCT04532060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Study NCT04532060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy
Study NCT01362036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
Study NCT00921232 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: During a consultation:~* 3 questionnaires (HADS, FRI, CRA)~* and a form for the sociodemographic data
Study NCT01797211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
Study NCT02209077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT performed to collect data from the back of the eye
Description: comparative retinal parameters with Spectralis OCT
Study NCT03938805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy for insomnia
Description: Patients will be provided with psycho education on different cardiovascular diseases, sleep, insomnia, and provided with different behavioral techniques to improve their sleep. The participants in the intervention Group who receives the Internet-based cognitive behavioral therapy program will also have access to support given by a nurse specialized in sleep. A module is given each week during the 9-week intervention.
Study NCT03938805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group receiving 3 weeks internet-based education on sleep hygiene. A module is given each week during the 3 weeks.
Study NCT00181181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin 80 mg daily for 3 months
Study NCT00181181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo daily
Study NCT04269226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
Study NCT04269226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No recruitment maneuver
Description: Usual ventilation procedures will be applied.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
Study NCT00290433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.
Study NCT03655756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFx-Hu2.0
Description: Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).
Study NCT04258943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)
Study NCT03328663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARE
Description: Promote effective coping and reduce caregiving burden.
Study NCT03328663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE
Description: Promote effective coping and reduce caregiving burden.
Study NCT03328663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Transplant Care
Description: Standard cared administered by the hospital.
Study NCT03919708 — intervention group
Intervention type: DEVICE
Intervention: Retinal Birefringence Imager
Description: Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
Study NCT03248401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 200 mg/day
Study NCT03248401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg/day
Study NCT00871312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topical wound oxygen therapy
Description: 90 minutes 4 days per week Active Topical Oxygen Therapy
Study NCT00871312 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Topical wound oxygen Placebo
Description: 90 mins per day 4 days per week Placebo Therapy
Study NCT00253630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00253630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT01780831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: RAL was given as oral granules for suspension.
Study NCT02642133 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lingual Frenotomy and/or maxillary labial frenectomy
Description: The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
Study NCT02360020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XLimus
Description: Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
Study NCT03946709 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Action Observation
Description: Strength, voluntary activation, and cortical responses to three conditions will be measured: 1) action observation of very strong, forceful contractions of the hand and wrist flexors 2) action observation of very weak, feeble contractions of the hand and wrist flexors 3) no action observation. Experimental conditions will be randomized and counterbalanced.
Study NCT02592850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.~Duration: 45 minutes. Administered once a week for four weeks.
Study NCT02592850 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.~Duration: 45 minutes. Administered once a week for four weeks.
Study NCT03992937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Micronized Progesterone
Description: Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
Study NCT03992937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-Intrauterine System
Description: Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.